Monthly Prescribing Reference

Letybo Approved to Treat Moderate to Severe Glabellar Lines

The potency units of Letybo are not interchangeable with other preparations of botulinum toxin products. The Food and Drug Administration (FDA) has approved Letybo (letibotulinumtoxinA-wlbg) for the ...
Healio

FDA approves Daxxify for glabellar line improvement

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the neuromodulator injection Daxxify for the temporary improvement of moderate to severe ...
Healio

Split-face study finds no difference between neurotoxins for glabellar lines

Please provide your email address to receive an email when new articles are posted on . A split-face comparison found no difference between onabotulinumtoxinA and prabotulinumtoxinA for the treatment ...
Nasdaq

Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States ...
Business Wire

Croma Aesthetics Canada Ltd. Receives Canadian Market Authorization for Letybo (LetibotulinumtoxinA for Injection) for the Treatment of Glabellar Lines

TORONTO--(BUSINESS WIRE)--Croma Aesthetics Canada Ltd., doing business as Hugel Aesthetics, today announced it received a Notice of Compliance from Health Canada for Letybo (letibotulinumtoxinA for ...
Business Wire

Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States ...